Adaptimmune Appoints Lawrence M. Alleva to its Board of Directors
News Mar 11, 2015
Adaptimmune has announced the appointment of Lawrence (Larry) M. Alleva, to its Board of Directors as an independent, non-executive director with immediate effect. Mr. Alleva will also serve as chairman of the Board Audit Committee.
Mr. Alleva is a former partner with PricewaterhouseCoopers LLP (PwC), where he worked for 39 years until his retirement in June 2010, including 28 years’ service as a partner. Mr. Alleva worked with numerous pharmaceutical and biotechnology companies as clients and, additionally, served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader for the firm’s Assurance Practice from 2006 until his retirement.
Mr. Alleva currently serves as a director for public companies Tesaro Inc. and Bright Horizons Family Solutions Inc., and for privately held Mirna Therapeutics Inc., and chairs the audit committee for those companies. He previously served on the board of GlobalLogic, Inc. through the sale of the company in 2013 and also chaired the audit committee. Mr. Alleva is a Certified Public Accountant (inactive). He received a Bachelor of Science degree in Accounting from Ithaca College and attended Columbia University’s Executive MBA non-degree program.
“I am delighted that such a high caliber individual as Larry Alleva has agreed to join our Board of Directors,” said Dr. Jonathan Knowles, Chairman of Adaptimmune. “His substantial corporate finance and accounting expertise, combined with his extensive experience of supporting growing biotech firms, brings significant added value to the Company, and complements the skills and experience of our other Board members.”
Mr. Alleva said: “I am very pleased to be joining Adaptimmune at this interesting time, and I look forward to working closely with the team as we aim to build the Company up with the expansion of its UK and US operations.”
Gene Regulator May Contribute to Protein Pileup in Exfoliation GlaucomaNews
Researchers are seeking factors that contribute to protein pileup in exfoliation glaucomaREAD MORE
Working Together Helps Phage Overcome CRISPRNews
Surprising results show that phage join forces to overcome bacteria’s CRISPR -based immune defenses. Improved understanding of the interactions between phage and their bacterial hosts could help advance phage-based therapies and stimulate viral research.READ MORE
The “Traffic Cop” Protein Which Gives Progenitor Cells Permission to DifferentiateNews
Knowledge of this dictating protein may help find therapies for the injured brain and affect glial tumor cell researchREAD MORE